इसराइल - अंग्रेज़ी - Ministry of Health

rafa laboratories ltd - budesonide - granules gastro-resistant - budesonide 9 mg - budesonide - acute mild to moderate crohn’s disease with involvement of the ileium (twisted intestine) and/or ascending colon (part of large bowel).collagenous colitis.

इसराइल - अंग्रेज़ी - Ministry of Health

rafa laboratories ltd - budesonide - tablets orodispersible - budesonide 1 mg - budesonide - treatment of eosinophilic esophagitis (eoe) in adults.

इसराइल - अंग्रेज़ी - Ministry of Health

rafa laboratories ltd - budesonide - tablets orodispersible - budesonide 0.5 mg - budesonide - treatment of eosinophilic esophagitis (eoe) in adults.

यूनाइटेड किंगडम - अंग्रेज़ी - myHealthbox

caduceus pharma ltd. - pemetrexed - concentrate for solution for infusion - 25mg - folic acid analogues - malignant pleural mesothelioma pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; purified talc; polysorbate 80; hypromellose; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; macrogol 6000 - treatment of chronic cholestatic liver diseases

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 3000 mg - granules, modified release - excipient ingredients: aspartame; carmellose sodium; microcrystalline cellulose; citric acid; hypromellose; magnesium stearate; methylcellulose; povidone; colloidal anhydrous silica; simethicone; sorbic acid; purified talc; titanium dioxide; triethyl citrate; methacrylic acid copolymer; flavour - salofalk granules granules are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1000 mg - suppository, moulded - excipient ingredients: hard fat - treatment of ulcerative proctitis

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1500 mg - granules, modified release - excipient ingredients: sorbic acid; magnesium stearate; triethyl citrate; hypromellose; methylcellulose; aspartame; povidone; purified talc; microcrystalline cellulose; methacrylic acid copolymer; carmellose sodium; simethicone; citric acid; colloidal anhydrous silica; titanium dioxide; flavour - salofalk granules are indicated for the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: sodium carbonate; glycine; povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000; basic butylated methacrylate copolymer - salofalk granules and tablets are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis. treatment of acute episodes and maintenance of remission of crohn's ileitis and colitis.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - irbesartan -